AbbVie Reports Strong First-Quarter Results with Revenue Growth and Outperforming Immunology Drugs
AbbVie reported first-quarter revenue of $15 billion, exceeding expectations, driven by strong performance in its immunology segment, particularly from drugs Skyrizi and Rinvoq. The results led to a 3% stock increase post-earnings, signaling potential for a sustained rally. The company's overall business remains robust despite underperformance earlier in the year.
Tickers: $ABBV
Topics: AbbVie Earnings Pharmaceuticals Revenue Stock Performance